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Objective: Chronic immune activation and elevated numbers of circulating activated monocytes (CD16 þ ) are implicated in HIV-associated neuroinflammation. The objective was to compare the level of circulating CD16 þ monocytes and IFN-g-inducible protein 10 (IP-10) between HIV-infected cannabis users (HIVþMJþ) and noncannabis users (HIVþMJÀ) and determine whether in-vitro D
9
-Tetrahydrocannabinol (THC), a constituent of cannabis, affected CD16 expression as well as IP-10 production by monocytes.
Design: The levels of circulating CD16
þ monocytes and IP-10 from HIVþMJÀ and HIVþMJþ donors were examined. In-vitro experimentation using THC was performed on primary leukocytes isolated from HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors to determine if THC has an impact on CD16 þ monocyte and IP-10 levels.
Methods: Flow cytometry was used to measure the number of blood CD16 þ monocytes and plasma IP-10 from HIVþMJÀ and HIVþMJþ donors. Peripheral blood mononuclear cells were isolated from HIVÀMJÀ and HIVþ (MJÀ and MJþ) donors for in-vitro THC and IFNa treatment, and CD16 þ monocytes and supernatant IP-10 were quantified.
Results: HIVþMJþ donors possessed a lower level of circulating CD16
þ monocytes and plasma IP-10, compared with HIVþMJÀ donors. Further, monocytes from HIVþMJþ donors were unable to induce CD16 expression when treated with in-vitro IFNa, whereas HIVÀMJÀ and HIVþMJÀ donors displayed pronounced CD16 induction, suggesting anti-inflammatory effects by cannabis. Lastly, in-vitro THC treatment impaired CD16
À monocyte transition to CD16 þ and monocyte-derived IP-10.
Introduction
Antiretroviral therapy (ART) has shifted HIV prognosis to a controllable disease; however, health complications remain and include cognitive decline, cardiovascular disease and malignancies [1] . Cognitive decline impacts 30-50% of HIV-infected (HIVþ) individuals and is termed HIV-associated neurocognitive disorder (HAND) [2, 3] . The cause of HAND is not fully understood but is due, in part, to dysfunction, damage and ultimately death of neurons, in the absence of productive HIV infection of neurons [4, 5] . Chronic immune activation and central nervous system (CNS) inflammation are mechanisms underlying neuronal damage [6, 7] . A growing body of evidence implicates CD16 þ monocytes as a contributor to this neuroinflammation [6, 8, 9] . Specifically, increased levels of CD16 þ monocytes in circulation have been observed in patients with chronic HIV infection and HIV-associated dementia [10] [11] [12] . Studies involving animal models and postmortem HAND patients have identified an increased level of CD16 þ monocytes in the CNS, and these cells stained positive for the HIV viral capsid protein, p24 [13] [14] [15] [16] . þ ) monocyte populations, are often termed 'inflammatory' monocytes due to their ability to secrete proinflammatory cytokines and promote T-cell activation [17, 18] . Elevated levels of CD16 þ monocytes in circulation have been observed in chronic inflammatory diseases including viremic HIV infection, multiple sclerosis and systemic lupus erythematosus [10, 19, 20] .
CD16
þ monocytes have been identified as the major monocyte population infected with HIV in circulation [21] . In addition, CD16 þ monocytes of HIV-infected individuals have increased expression of cell adhesion molecules and the chemokine receptor, CC chemokine receptor 2, in comparison with CD16 À monocytes, resulting in enhanced migration across in-vitro models of the blood brain-barrier [22] . CD16 þ monocytes are thought to be a major transport mechanism for HIV into the brain while also being able to secrete neurotoxic factors and proinflammatory cytokines [7] [8] [9] 13, 16] . IFN-g-inducible protein 10 (IP-10/C-X-C motif chemokine 10) is a proinflammatory factor secreted by monocytes during HIV infection and may play a key role in HIV-associated neuroinflammation [23, 24] . IP-10 is elevated in the plasma and cerebrospinal fluid (CSF) of patients with HAND and plasma levels inversely correlated with N-acetylaspartate, a marker of neuronal injury [25] [26] [27] . Furthermore, in-vitro experiments have revealed neurotoxic effects by IP-10 as evidenced by apoptosis of neurons [28] .
A surface marker expressed by CD16 þ monocytes is CD163 [29, 30] . Coexpression of CD16 and CD163 on monocytes has been observed at an increased level in postmortem brain tissue of HIVþ individuals with cognitive impairment [14, 15] . CD16 þ CD163 þ monocytes are also elevated in circulation of HIVþ individuals with detectable viral loads [31] , suggesting that CD163 is expressed on CD16 þ monocytes before entry into the brain. In addition, CD163 has been shown to have an important role for monocyte adherence to endothelial cells [32] , providing a functional role for its expression on CD16 þ monocytes that are migrating to the brain.
À monocytes transition into the CD16 þ phenotype in circulation, and this process is of interest due to the pathogenic nature of the CD16 þ monocyte subset during HIV infection [8, 18] . However, the specific mechanism(s) of enhanced CD16
À monocyte transition to CD16 þ during HIV infection remains unclear. Here we considered IFNa as a potential inducer of CD16
À to CD16 þ monocyte transition. This is supported by previous studies in which monocytes isolated from HIV-infected individuals displayed a type I interferon gene signature, suggesting exposure to IFNa in vivo [25, 33] . In addition, the use of IFNa as a vaccine adjuvant in humans increased the percentage of CD16 þ monocytes [34] . IFNa is a central component of the innate antiviral immune response against HIV infection, but elevated IFNa can persist during the chronic stages of infection [35] . Sustained presence of IFNa is thought to contribute to the chronic immune activation and neurocognitive dysfunction observed during HIV pathogenesis [35] [36] [37] .
Cannabis use is common amongst HIV-infected individuals in the United States and Canada, with an estimated prevalence of 20-37% [38] [39] [40] . HIVþ individuals use cannabis to help alleviate symptoms of HIV infection [41, 42] . The major psychotropic cannabinoid in cannabis, D 9 -Tetrahydrocannabinol (THC), has been identified as an immune modulator in animal models and cell-based systems, with most of its effects characterized as being immune suppressive and anti-inflammatory [43, 44] . THC modulates immune cell activity, in part, by binding cannabinoid receptor 1 and 2 (CB1 and CB2) [43] . In human monocytes, CB2 mRNA expression is higher than CB1, with both CB1 and CB2 being expressed at the protein level [45] .
The central observation for the development of this study is that HIV-infected individuals using cannabis (HIVþMJþ) have lower levels of circulating CD16 þ monocytes and plasma IP-10 in comparison with HIVinfected persons not using cannabis (HIVþMJÀ). From this initial observation, the objective of this study was to use human primary leukocytes isolated from HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors to determine whether in-vitro IFNa promotes monocyte expression of CD16 and CD163, the effects of in-vitro THC treatment on the percentage of monocytes expressing CD16 and/or CD163 in response to IFNa, and the effect of THC on monocyte production of IP-10. Collection of plasma and leukocytes from whole blood of HIVSMJS, HIVRMJS and HIVRMJR donors Whole blood was collected from HIVÀMJÀ (Stanford Blood Center) and HIVþ donors in acid citrate dextrose (ACD) or heparin tubes and either shipped (HIVÀMJÀ donors) or stored (HIVþ donors) overnight at room temperature. The next day, the number of leukocytes per milliliter of blood was obtained using a coulter counter. An aliquot of cells from whole blood collected in ACD or heparin tubes was used for cell surface staining. Before surface staining, red blood cells were removed using ammonium-chloride-potassium lysis buffer. For plasma collection, whole blood was collected in heparin tubes only. Plasma was collected and stored at À80 8C.
Materials and methods

HIV-infected donors
Peripheral blood mononuclear cell and CD16
S monocyte isolation for in-vitro studies Peripheral blood mononuclear cells (PBMCs) were isolated from human leukocyte packs (Gulf Coast Regional Blood Center, Houston, Texas, USA) of HIVÀMJÀ donors and whole blood of HIVþ (MJÀ and MJþ) donors by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, USA). Purified CD16 À monocytes were isolated by negative selection using Human Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) per manufacturer's direction. The mean (AESD) monocyte purity for donors (N ¼ 14) used in this report was 88.4 AE 5.7%. The mean percentage of CD16 À cells within the monocyte population was 99.2 AE 0.6% (<1% CD16 þ monocytes).
Chemicals THC and cannabidiol (CBD) were dissolved in 100% ethanol (National Institute on Drug Abuse, Bethesda, Maryland, USA). For cell culture experiments, THC and CBD were serially diluted in RPMI 1640. The vehicle concentration for each treatment was 0.03% ethanol.
Cell culture and activation PBMCs (5 Â 10 6 cells/ml) or purified CD16 À monocytes (1 Â 10 6 cells/ml) were cultured in media containing RPMI1640 (Gibco) supplemented with 5% human AB serum (Sigma-Aldrich, St. Louis, Missouri, USA) and 100 U/ml Penicillin/100 mg/ml streptomycin (Gibco). Leukocytes were stimulated with Universal Type I Interferon Alpha (PBL Assay Science, Piscataway Township, New Jersey, USA) and incubated at 37 8C and 5% CO 2 . For experiments involving THC/CBD treatment, cells were incubated at 37 8C and 5% CO 2 with the corresponding concentration of THC/CBD for 30 min prior to IFNa addition.
Flow cytometry
Fluorescence-activated cell sorting (FACS) buffer (PBS, 1% BSA, 0.1% NaN 3 ) was used to wash cells in between staining and fixing steps. First, cells were incubated with FACS containing 20% human AB serum to block Fc receptors. Cells were then incubated with antibodies and LIVE/DEAD Fixable Near-IR Dead Cell Stain (Thermo Fisher Scientific, Waltham, Massachusetts, USA). BD Cytofix (BD Biosciences, San Jose, California, USA) was used to fix cells. For intracellular staining, cells were stained with antibody in BD Perm/Wash (BD Biosciences). Fixed cells were analyzed on a FACS BD Canto II (BD Biosciences). Antibodies included anti-CD14-PeCy7 (clone: M5E2), anti-CD16-APC (3G8) and anti-CD163-BV421 (GHI/61) from BioLegend (San Diego, California, USA) and anti-IFNAR2-APC-Vio770 (REA124) from Miltenyi Biotec. Anti-IP-10-PerCPeFluor710 (4NY8UN) antibody was purchased from eBioscience (San Diego, California, USA). For intracellular IP-10 staining, a protein transport inhibitor (eBioscience) was added to cell culture 5 h prior to experiment takedown. Data analysis was performed using FLOWJO v10 software (FLOWJO, LLC, Ashland, Oregon, USA). The gating strategy for CD16 þ monocytes is in Supplementary Fig. 1 (refer to figure, Supplemental Digital Content 1, http://links.lww.com/ QAD/B197). A Boolean gate was used to determine the percentage of CD16
þ cells within the monocyte population. For experiments involving purified monocytes, viable monocytes were gated on the basis of sidescattered light and forward-scattered light area and analyzed for CD16 and CD163 expression.
Plasma and supernatant IFN-g-inducible protein 10 analysis Plasma or supernatants were collected and stored at À80 8C. Plasma/supernatants were thawed and IP-10 protein levels were quantified using LEGENDplex (Biolegend, San Diego, California, United States) or ELISAmax (Biolegend, San Diego, California, United States) per manufacturer's direction.
Statistical analysis
Statistical analysis was performed using Prism 7 (GraphPad, San Diego, California, USA). The experimental data was graphed as the mean AE SEM. The statistical tests performed for each experiment are indicated in the figure legends.
Results
HIVRMJR donors possess lower levels of circulating CD16
R monocytes and plasma IFN-g-inducible protein 10 compared with HIVRMJS donors Monocyte expression of CD16 and CD163, and plasma IP-10 was determined in whole blood collected from HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors. There were no significant differences in age, BMI, CD4 þ cell count, CD4
þ /CD8 þ ratio and years infected with HIV between HIVþMJÀ and HIVþMJþ donors. In addition, there was a similar profile between HIVþMJÀ and HIVþMJþ donors in terms of being on ART, having undetectable viral loads, cigarette use, alcohol and other drugs of abuse (refer to table, Supplemental Digital Content 2, http://links.lww.com/QAD/B197). When the levels of CD16 þ monocytes were compared, HIVþMJþ donors had a significantly lower level compared with HIVþMJÀ donors (P ¼ 0.026) (Fig. 1a) . A lower number of CD16 þ CD163 þ monocytes was also observed in HIVþMJþ donors when compared with HIVþMJÀ donors but NS (P ¼ 0.052) (Fig. 1b) . In addition, plasma IP-10 was also significantly lower in HIVþMJþ donors compared with HIVþMJÀ donors (P ¼ 0.005) (Fig. 1c) .
IFNa treatment of peripheral blood mononuclear cells and purified monocytes increases the expression of both CD16 and CD163 on monocytes in HIVSMJS and HIVRMJS donors but not HIVRMJR donors Monocyte transition into the CD16 þ phenotype in circulation is a key step prior to monocyte migration into the CNS during HIV infection [13, 46] , but the specific mechanism(s) of this monocyte transition remains unclear. As a type I IFN gene signature has been identified in monocytes from HIVþ individuals [25, 33] , we sought to determine the effect of IFNa on monocyte expression of CD16 and CD163. Human PBMCs isolated from HIVÀMJÀ donors were stimulated with 50U/ml of IFNa, and cells were harvested at 6, 16, 24 and 48-h poststimulation. Supplementary Digital Content 3, http://links.lww.com/QAD/B197 illustrates the effect of IFNa on monocyte expression (within PBMCs) of CD16 at 48 h. IFNa treatment for 48 h led to a significant increase in the percentage of monocytes expressing CD16 (P < 0.0001) (Fig. 2a) , whereas a significant increase in percentage of CD163 þ monocytes was observed only at 24 h (P ¼ 0.01) (Fig. 2b) . There was a notable increase in the percentage of CD163 þ monocytes in the nonstimulated monocytes at 48 h, which may be due to adherence-mediated activation of monocytes [47] . A significant increase in the percentage of monocytes coexpressing CD16 and CD163 (CD16 þ CD163 þ ) was observed at 48 h (P < 0.0001) (Fig. 2c ). PBMCs were then isolated from HIVþMJÀ and HIVþMJþ donors to determine if there was a difference in the IFNa-mediated induction of CD16 and CD163 on monocytes from HIVþMJÀ and HIVþMJþ donors. Importantly, IFNa treatment significantly increased the percentage of monocytes expressing CD16 (P ¼ 0.027), CD163 (P ¼ 0.002) and CD16/ CD163 (P ¼ 0.009) in HIVþMJÀ donors (Fig. 2d-f) , which was similar to that of HIVÀMJÀ donors. 
CD163
þ monocytes and plasma IFN-g-inducible protein 10 (pg/ml) was measured. For (a-c), data were log transformed and a one-way ANOVA with a Dunnett's post-hoc test was performed (P < 0.05). All graphs are mean AE SEM. ANOVA, analysis of variance.
However, IFNa treatment only increased the percentage of CD163 þ monocytes (P ¼ 0.005) and not CD16 (Fig. 2d-f) , suggesting that cannabis use may be suppressing monocyte induction of CD16.
To determine if IFNa is having a direct role on monocyte expression of CD16 and CD163, CD16
À monocytes from HIVÀMJÀ and HIVþMJÀ donors were purified prior to IFNa (50 U/ml) treatment. As with PBMCs, IFNa treatment of purified monocytes led to an increased percentage of CD16 þ , CD163 þ and CD16 þ CD163 þ monocytes for both HIVÀMJÀ (P ¼ 0.032, 0.0001 and 0.0007, respectively) and HIVþMJÀ (P ¼ 0.017, 0.0007 and 0.0005, respectively) donors (Fig. 2g-i) .
In-vitro D
9
-tetrahydrocannabinol treatment of HIVSMJS peripheral blood mononuclear cells and purified monocytes impairs the IFNamediated induction of CD16 and CD163 expression on monocytes As HIVþMJþ donors have lower levels of CD16 þ and CD16 þ CD163 þ monocytes (P ¼ 0.052) in whole blood compared with HIVþMJÀ donors, we sought to determine whether in-vitro THC treatment influenced monocyte expression of CD16 and CD163 in response to IFNa. PBMCs from HIVÀMJÀ donors were pretreated with 1, 5 and 10 mmol/l of THC and stimulated with IFNa (50 U/ml) for 48 h. THC treatment markedly decreased the percentage of CD16 þ monocytes in a concentration-dependent manner with significant suppression at 1, 5 and 10-mmol/l THC (P < 0.0003 for all
HIV-infected cannabis users have fewer CD16
R monocytes Rizzo et al. THC concentrations) (Fig. 3a) . In addition, THC treatment significantly decreased the percentage of CD163 þ (P < 0.005 for 5 and 10 mmol/l) and CD16 þ CD163 þ (P < 0.0006 for all THC concentrations) monocytes (Fig. 3b and c) . THC treatment had no significant effect on cell viability (>95% for each treatment group). As IFNa modulates cell function through the IFNa/b receptor (IFNAR) [48] , we next sought to determine the effect of THC on monocyte expression of IFNAR using the same experimental approach as above. THC at 10 mmol/l modestly decreased the percentage of IFNAR þ monocytes after 48 h of IFNa treatment (P ¼ 0.023) (Fig. 3d) .
To determine if THC has a direct inhibitory effect on the monocyte population and not influencing monocyte activation via a bystander effect, CD16 À monocytes from HIVÀMJÀ PBMCs were purified, pretreated with 0.5, 1, 5 and 10 mmol/l of THC and stimulated with IFNa (50 U/ml) for 48 h. As seen in PBMCs, THC treatment decreased all three monocyte populations (CD16 þ , CD163 þ and CD16 þ CD163 þ ) in a concentration-dependent manner (grey bars in Fig. 3e-g ). Next, we confirmed that THC treatment also directly impaired monocyte expression of CD16 and CD163 in purified monocytes of HIVþMJÀ donors (black bars in Fig. 3e-g ). THC treatment had no effect on cell viability (>95% for each treatment group).
Cannabidiol does not impair CD16 or CD163 expression in IFNa-stimulated peripheral blood mononuclear cells from HIVSMJS donors THC has a binding affinity to both CB1 and CB2 with a Ki of 25.1 and 35.2 nmol/l for CB1 and CB2, respectively [49] . By contrast, CBD, another cannabinoid present in cannabis, displays high structure similarity to THC but has 80-fold lower binding affinity to CB1 and CB2 [49] . To better understand the role of CB1/CB2 in the THC-mediated impairment of CD16 and CD163 expression on monocytes, PBMCs from HIVÀMJÀ donors were pretreated with THC or CBD at 1, 5 and 10 mmol/l and stimulated with 50 U/ml of IFNa for 48 h. As observed in Fig. 3 , THC significantly decreased the percentage of monocytes expressing of CD16 (P ¼ 0.0001 for 10-mmol/l THC), CD163 (P ¼ 0.004 for 10-mmol/l THC) and CD16/CD163 (P ¼ 0.0001 for 10-mmol/l THC), whereas CBD at the same concentrations elicited no significant effects on the percentage of monocytes expressing of CD16 (P ¼ 0.448 for 10-mmol/l THC), CD163 (P ¼ 0.626 for 10-mmol/l THC) and CD16/CD163 (P ¼ 0.219 for 10-mmol/l THC) (Fig. 4a-c) . þ monocytes (Fig. 5a ). Of the IP-10 þ monocytes in the IFNa treatment group, 73% were CD16
À and 27% were CD16 þ (P ¼ 0.126) (data not shown), suggesting that CD16 expression is not a prerequisite for monocyte production of IP-10. Next, PBMCs from HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors were pretreated with 1 and 5-mmol/l THC and stimulated with IFNa for 48 h. IFNa triggered a significant increase in supernatant IP-10 levels in the three donor groups (P < 0.009), with no significant differences detected across groups (Fig. 5b1) . IP-10 levels were suppressed by 1 and 5-mmol/l THC in HIVÀMJÀ donors (P ¼ 0.028 for 1 mmol/l and P ¼ 0.004 for 5-mmol/l THC), whereas significant suppression was only seen at 5-mmol/l THC in HIVþMJÀ (P ¼ 0.009) and HIVþMJþ (P ¼ 0.004) donors (Fig. 5b2) . To determine if THC directly impairs monocyte production of IP-10, monocytes were purified from HIVÀMJÀ and HIVþMJÀ donors, treated with THC (0.5, 1, 5 and 10 mmol/l) and stimulated with IFNa for 48 h. IFNa stimulation significantly increased supernatant IP-10 in purified monocytes from HIVÀMJÀ and HIVþMJÀ donors (Fig. 5c1) . THC treatment decreased supernatant IP-10 in a concentration-dependent manner with significant differences observed at 0.5-10-mmol/l THC in both HIVÀMJÀ (P ¼ 0.019 for 0.5-mmol/l THC) and HIVþMJÀ (P ¼ 0.007 for 0.5-mmol/l THC) donors (Fig. 5c2) .
Discussion
In the current study, we show that IFNa treatment of PBMCs and purified monocytes isolated from HIVÀMJÀ donors promotes monocyte transition into the CD16 þ phenotype as well as increases the percentage of CD163 þ and CD16 þ CD163 þ monocytes. These findings coincide with previous studies reporting that monocytes from HIV-infected individuals display a type I interferon gene signature [25, 33] . Similarly, in-vivo IFNa therapy promoted an increase in the percentage of CD16 þ monocytes [34] . Taken together, these observations strongly support IFNa as an inflammatory factor that increases the frequency of CD16 þ and CD16 þ CD163 þ monocytes during HIV infection. These findings are noteworthy since circulating CD16 þ /CD16 þ CD163 þ monocytes traffic to the brain during HIV-infection promoting viral entry as well as secretion of inflammatory and neurotoxic factors [8, 9, 13, 16] . Significantly, the IFNa-mediated monocyte transition to CD16 þ was only observed in HIVþMJÀ donors and not HIVþMJþ donors, suggesting that cannabis use may impair the induction of CD16. Future studies investigating the differences in monocytes expression of IFNAR and key downstream signaling molecules between HIVþMJÀ and HIVþMJþ donors will provide insights into the lack of CD16 induction observed in HIVþMJþ donors.
After the initial observation that HIVþMJþ donors possess lower circulating CD16 þ and CD16 þ CD163 -tetrahydrocannabinol on IFN-g-inducible protein 10 levels is displayed on the right. For (b2) and (c2), IFN-g-inducible protein 10 levels for each D
9
-tetrahydrocannabinol treatment group was normalized to the donors vehicle control response (e.g. 0 mmol/l D 9 -tetrahydrocannabinol), which served as 100%. For (b1) and (c1), Ã denotes a statistical difference from nonstimulated controls (P < 0.05, two-way ANOVA with a Sidak's multiple comparisons test). For (b2) and (c2), Ã denotes a statistical difference from vehicle control (50 U/ml IFNa þ vehicle) group (P < 0.05) (RM one-way ANOVA with a Dunnett's multiple comparisons posttest). Graphs in (b) and (c) are mean AE SEM. ANOVA, analysis of variance; RM, repeated measures. treatment impaired monocyte expression of IFNAR in HIVÀMJÀ donors; however, the impairment was modest and only observed at the highest concentration of THC (10 mmol/l). With significant impairment in CD16 expression seen as low as 1 mmol/l THC, these findings suggest that THC is impairing IFNAR-mediated signaling. THC impairment of CD16 and CD163 expression on monocytes was also observed in purified CD16
À monocytes demonstrating that THC acts directly on the monocyte population and not through a bystander mechanism. Further, treatment with the low affinity CB1/CB2 agonist, CBD, yielded no significant effect on CD16 or CD163 expression, suggesting that THC is modulating monocyte activity through a CB1/CB2-dependent mechanism. As HIV-infected individuals have chronic immune activation [50, 51] and CB1/CB2 expression may change with monocyte/macrophage activation status [43] , the sensitivity of immune cells to THC treatment may vary between HIVÀMJÀ and HIVþMJÀ donors. Therefore, we performed experiments using monocytes from HIVþMJÀ donors, which demonstrated that monocytes isolated from HIVþMJÀ donors displayed similar impairment by THC on CD16 and CD163 expression to that of HIVÀMJÀ donors. Overall, these findings suggest that the THC present in cannabis may be a significant contributor to the decreased levels of CD16 þ monocytes observed in HIVþMJþ donors.
Another interesting observation in this study is that plasma IP-10 levels are lower in HIVþMJþ donors compared with HIVþMJÀ donors. IP-10 has been shown to be elevated in the CSF of patients with cognitive impairment and is thought to be an important contributor to neuroinflammation during HIV infection [24] . Furthermore, IP-10 has been shown to stimulate HIV replication in monocyte-derived macrophages and promote neuronal apoptosis in vitro [28, 52] . Using intracellular IP-10 staining, we report that the monocyte population is the primary cell type within the PBMCs of HIVÀMJÀ donors secreting IP-10 in response to IFNa and monocyte expression of CD16 is not necessary for IP-10 production. This is in agreement with a previous report showing the monocyte population is a major source of IP-10 when stimulated with TLR7/8 ligands [23] . When comparing the IFNa-mediated induction of IP-10 between HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors, similar induction profiles were observed. THC treatment was shown to decrease IP-10 in all three groups, with HIVÀMJÀ donors showing a slight increase in sensitivity to THC. Using purified monocytes from HIVÀMJÀ and HIVþMJÀ donors, we demonstrate that THC has a direct effect on the monocytes resulting in decreased IP-10 levels. Furthermore, THC at a concentration of 0.5 mmol/l significantly decreased IP-10 levels, which is within the concentration range observed in blood of individuals smoking cannabis [53] .
The results from the current study show that in-vitro THC treatment promotes anti-inflammatory effects on monocyte processes that are implicated in HIV-associated neuroinflammation, including monocyte transition into the CD16 þ phenotype and secretion of IP-10. With these findings it is tempting to speculate that THC is one of the major components of cannabis that elicits the decrease in circulating CD16
þ monocytes and plasma IP-10 that was observed in HIVþMJþ donors. However, the in-vivo effects of THC when inhaled through cannabis use may be different than that observed in vitro due to the additional 60-plus cannabinoids that are present in cannabis as well as other plant-derived constituents [54] . Therefore cannabinoids in combination with other plant-associated compounds may contribute to the observed anti-inflammatory actions. In addition, cannabis use could indirectly have anti-inflammatory actions, such as through stress reduction, which can have an impact on inflammation [55, 56] .
There were limitations in the cross-sectional design comparing blood CD16 þ monocytes and plasma IP-10 in HIVÀMJÀ, HIVþMJÀ and HIVþMJþ donors (Fig. 1) . First, the absence of HIVÀMJþ donors hindered our ability to make comparisons between HIVÀMJþ and HIVþMJþ donors. However, the HIVÀMJÀ donors served as a comparator to show the increased levels of inflammatory markers observed in HIVþMJÀ donors. The central focus was to identify potential differences in the number of monocytes expressing CD16/CD163 and plasma IP-10 between HIVþMJÀ and HIVþMJþ donors. Second, the exposure level of cannabis in the HIVþMJþ population could not be quantified due to many variables. This remains a systemic limitation in studies investigating cannabis use, as exposure levels can be influenced by multiple variables [57] . However, we could confirm cannabis use and whether respondents were accurate in stating cannabis use in the patient questionnaire by assaying blood samples for the presence of THC metabolites. Lastly, the HIVÀMJÀ donors in this study were from different geographical locations compared with the HIVþMJÀ and HIVþMJþ donors. Importantly, all HIVþ donors, HIVþMJÀ and HIVþMJþ, were from the Mid-Michigan area.
We conclude that within the context of HIV-associated neuroinflammation and cognitive decline, cannabinoid therapies may decelerate peripheral immune processes that are implicated in HIV-associated neuroinflammation.
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